Breast :乳腺癌的免疫预防疫苗或将问世

2013-11-01 孟秋君-编译 the breast journal

一项来自意大利博洛尼亚大学的最新研究显示,在小鼠实验模型上已成功研发了针对乳腺癌进行免疫预防的有效抑制疫苗。该临床前期结果为人类癌症免疫预防基因表达提供了有效参考,同时预示该疫苗可成功实现人类基因表达,属于肿瘤免疫治疗的阶梯形进步。 肿瘤免疫预防可在健康个体中加强免疫防御,并可有效控制肿瘤发病。在以往的研究中,病毒性肿瘤的预防已在人类肝癌

自意大利博洛尼亚大学的最新研究显示,在小鼠实验模型上已成功研发了针对乳腺癌进行免疫预防的有效抑制疫苗。该临床前期结果为人类癌症免疫预防基因表达提供了有效参考,同时预示该疫苗可成功实现人类基因表达,属于肿瘤免疫治疗的阶梯形进步。【原文下载

肿瘤免疫预防可在健康个体中加强免疫防御,并可有效控制肿瘤发病。在以往的研究中,病毒性肿瘤的预防已在人类肝癌与宫颈癌群体水平上得到实现。总的来讲,病毒性疫苗可阻止10%以上人类肿瘤的发病。但是,是否该疫苗同时适用于包括乳腺癌在内的非病毒性肿瘤在以往研究中还处于空白阶段。

已在临床前期模型中获得针对具有乳腺癌发展倾向的 HER-2/neu 转基因鼠使用对抗HER-2/neu P185癌基因蛋白疫苗后的研究结果,且该结果颇具前景。保护性免疫机制主要是基于T细胞因子的帮助,特别是伽玛干扰素和反-p185抗体,由疫苗的有效性得到确认。将那些抑制肿瘤增长的抗肿瘤基因模型,特别是针对HER-2起到良好抑制作用的肿瘤模型,对于抑制肿瘤增长是必不可少的。因此代表了肿瘤免疫预防目标的最佳分类。针对免疫预防疫苗对抗肿瘤进展后续阶段的研究结果发现对抗乳腺癌显著失去药效,然而肿瘤恶性进展被成功抑制。

原文出处

Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Nanni P.Immunoprevention and immunotherapy of mammary carcinoma.Breast J. 2010 Sep-Oct【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=338191, encodeId=43cf338191b7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Aug 12 21:55:10 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710677, encodeId=050b1e10677c4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 24 18:08:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820138, encodeId=52491820138de, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Nov 10 19:08:00 CST 2013, time=2013-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351055, encodeId=fdca13510550b, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 03 02:08:00 CST 2013, time=2013-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402570, encodeId=3a3214025e0f9, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Sun Nov 03 02:08:00 CST 2013, time=2013-11-03, status=1, ipAttribution=)]
    2018-08-12 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=338191, encodeId=43cf338191b7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Aug 12 21:55:10 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710677, encodeId=050b1e10677c4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 24 18:08:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820138, encodeId=52491820138de, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Nov 10 19:08:00 CST 2013, time=2013-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351055, encodeId=fdca13510550b, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 03 02:08:00 CST 2013, time=2013-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402570, encodeId=3a3214025e0f9, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Sun Nov 03 02:08:00 CST 2013, time=2013-11-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=338191, encodeId=43cf338191b7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Aug 12 21:55:10 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710677, encodeId=050b1e10677c4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 24 18:08:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820138, encodeId=52491820138de, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Nov 10 19:08:00 CST 2013, time=2013-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351055, encodeId=fdca13510550b, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 03 02:08:00 CST 2013, time=2013-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402570, encodeId=3a3214025e0f9, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Sun Nov 03 02:08:00 CST 2013, time=2013-11-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=338191, encodeId=43cf338191b7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Aug 12 21:55:10 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710677, encodeId=050b1e10677c4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 24 18:08:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820138, encodeId=52491820138de, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Nov 10 19:08:00 CST 2013, time=2013-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351055, encodeId=fdca13510550b, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 03 02:08:00 CST 2013, time=2013-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402570, encodeId=3a3214025e0f9, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Sun Nov 03 02:08:00 CST 2013, time=2013-11-03, status=1, ipAttribution=)]
    2013-11-03 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=338191, encodeId=43cf338191b7, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Aug 12 21:55:10 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710677, encodeId=050b1e10677c4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Sep 24 18:08:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820138, encodeId=52491820138de, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Nov 10 19:08:00 CST 2013, time=2013-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351055, encodeId=fdca13510550b, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 03 02:08:00 CST 2013, time=2013-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402570, encodeId=3a3214025e0f9, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Sun Nov 03 02:08:00 CST 2013, time=2013-11-03, status=1, ipAttribution=)]

相关资讯

AJHG:科学家发现咽喉癌新基因ATR

伦敦大学国王学院与日本广岛大学的研究人员通过对一个家庭中10成员患有咽喉癌的遗传研究,已经鉴定出一个特定的基因与咽喉癌有关。 发表在3月8日The American Journal of Human Genetics上的研究揭示ATR基因突变,首次证实ATR基因的异常与遗传类型的癌症有关。研究人员说这一发现提示咽喉癌与遗传因素有关,并为探索ATR在癌症生物学的作用提供一个平台(奠定了基础)。

JNCI:肿瘤疫苗的现状与发展

首个癌症疫苗已通过FDA批准上市。据The Journal of the National Cancer Institute刊登的一则研究表明目前,一些针对一系列肿瘤相关抗原的癌症治疗疫苗正在进行临床试验评估。 肿瘤微环境和其他免疫抑制实体可能限制了癌症疫苗的有效性。为了克服避免这一现象,无论是疫苗与免疫关键节点(checkpoint)抑制剂、某些化疗药物和小分子靶向制剂、辐射疗法都要经过临床前

Ann Surg:肿瘤疫苗可改善结直肠癌患者转移灶切除术后生存结局

在2013年5月7日在线出版的《外科学年鉴》(Annals of Surgery)杂志上,发表了美国杜克大学Michael A. Morse博士等人的一项研究结果,该研究针对可进行手术切除的转移性结直肠癌患者(CRC),旨在考察基于树突状细胞(DC)及编码CEA(癌胚抗原)与MUC1 (PANVAC)痘病毒载体的一类或两类疫苗是否可以延长患者的生存时间。转移性CRC患者在接受完全切除后常出现复发。

科学家研发出通用性肿瘤疫苗 有望6年内问世

       科学家已研发出一种疫苗,它可以在癌症患者体内“巡视”并摧毁肿瘤细胞。        该疗法的靶点分子存在于90%的肿瘤细胞中,通过广泛地注射病人体内让其免疫系统对抗常见的癌症,包括乳腺癌和前列腺癌。早期临床实验中的初步结果表明,疫苗可以引起患者的免疫反应并改善癌症的病情。